You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Zepbound ® (tirzepatide) injection
2.5 mg/ 5 mg/ 7.5 mg/ 10 mg/ 12.5 mg/ 15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Zepbound® (tirzepatide) be used with oral contraceptives or hormone replacement therapy?
Yes, however, people using oral contraceptives should be advised to switch to a nonoral contraceptive method or add a barrier method for 4 weeks after initiation and for 4 weeks after each dose escalation. For HRT, there is no additional data.
See important safety information, including boxed warning, in the attached prescribing information.
Does Tirzepatide Affect Oral Contraceptive Efficacy?
Tirzepatide delays gastric emptying. The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.1
Because tirzepatide delays gastric emptying, it has the potential to impact the absorption of concomitantly administered oral medications, including oral contraceptives.1
Caution should be exercised when oral medications are concomitantly administered with tirzepatide.1
Monitor patients on oral medications that are dependent on threshold concentrations for efficacy and those with a narrow therapeutic index when used with tirzepatide.1
Use of tirzepatide may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time.1
Patients using oral hormonal contraceptives should be advised to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with tirzepatide.1
Hormonal contraceptives that are not administered orally should not be affected.1
Can Tirzepatide Be Used in Patients Taking Oral Hormonal Replacement Therapy?
There is no information on the use of tirzepatide in people taking oral hormonal replacement therapy because this has not been studied.
There have been no studies to measure the effect of tirzepatide on endogenous gonadotropins or sex steroids such as estrogen, progesterone, and testosterone.
Enclosed Prescribing Information
References
1Zepbound [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: February 25, 2026